Physiometrix, Inc. to Announce Fourth-Quarter and Year End Financial Results

Physiometrix, Inc. to Announce Fourth-Quarter and Year End
Financial Results
"We are encouraged by the continuing strong sales momentum into hospitals in
the fourth quarter" John A. Williams, Chief Executive Officer, Physiometrix,
Inc. 


NO. BILLERICA, Mass., Jan. 11  /PRNewswire-FirstCall/ -- Physiometrix, Inc.
(NASDAQ:PHYX) announced today it will report fourth-quarter and year end 2004
financial results and hold a telephone conference call to discuss the results,
as well as management's comments related to the Company's business, at 11:00
A.M. E.S.T. Thursday March 3, 2005. Call information will be made available
prior to that date.

John A. Williams, Chief Executive Officer, Physiometrix, Inc. comments, "Our
momentum in all phases of our business continues:

  -- PSA 4000 sales to hospitals by Baxter increased by 19% and disposable
     array sales by Baxter increased 45% as compared to Baxter's sales for
     the third quarter of 2004
  -- We continue to work with Baxter on increasing sales and an extension of
     our distribution agreement for the PSA 4000/5000
  -- The American Society of Anesthesiologists (ASA) taskforce continues its
     work on a practice parameter related to intra-operative brain
     monitoring, which is currently scheduled to be published in 2005
  -- We anticipate the completion of key studies in the intensive care unit
     (ICU) to support our product launch for ICU applications in 2005
  -- We are sponsoring a symposium along with Baxter at the Society of
     Critical Care meeting on January 16th. We expect that this symposium
     will serve as the introduction for our launch into the ICU
  -- The PSA 5000 is being readied for launch in both the operating room and
     ICU markets in mid-2005
  -- We anticipate adding to our sales and marketing staff to work in
     harmony with Baxter in increasing market share
  -- We are funding a critical clinical study in 2005 related to cognitive
     dysfunction in patients following general anesthesia. It is intended to
     highlight important safety concerns for patients and could be very
     influential in advancing the case for sedation monitoring as a standard
     of care
  -- A recent alert published by the Joint Commission on Accreditation of
     Healthcare Organizations (JCAHO) related to safety issues associated
     with general anesthesia appears to be having a positive effect on the
     number of evaluations requested by hospitals



We would like our shareholders to know that we are deeply committed to
advancing our best in class technology toward standard of care and are not
aware of any reason for the recent market activity in our stock. We look
forward to your support during this very exciting time for level of sedation
monitoring," Williams concluded.

Physiometrix Inc. designs, manufactures and markets noninvasive medical
products -- based on novel gel materials, sophisticated signal-processing
electronics technologies, and proprietary software -- for use in anesthesia-
monitoring during surgical procedures.  For more information, please visit the
Company's Web site at http://www.physiometrix.com/.

Statements in this press release regarding Physiometrix's growth and future
business results of the Company are "forward-looking" statements as defined in
the Private Securities Litigation Reform Act of 1995.  Such statements are
based upon management's current expectations and are subject to a number of
factors and uncertainties.  Information contained in these forward-looking
statements is inherently uncertain, and actual performance and results may
differ materially due to many important factors.  Such factors that could cause
actual results to differ materially from any forward-looking statements made by
the Company include, among others, revenue estimates, dependence on existing
and future products, dependence upon third-party distribution and sales
arrangements, the existence of alternative technologies and the potential
emergence of new methods for consciousness monitoring, uncertainty of market
acceptance, intense competition, partnership agreements, and government
regulations, especially regulatory approvals.  These and other relevant risks
are described in the Company's Form 10-K dated March 30, 2004 filed with the
SEC and the company's subsequent reports on form 10-Q filed for the first,
second and third quarters of fiscal 2004.  The Company disclaims any obligation
to update information contained in any forward-looking statement to reflect
events or circumstances occurring after the date of this press release. 

DATASOURCE: Physiometrix Inc.



CONTACT:  Daniel W. Muehl, CFO of Physiometrix Inc., [phone] 



Web site:  http://www.physiometrix.com/ 

Copyright